These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
223 related articles for article (PubMed ID: 36387113)
1. Novel small Liang Z; Hu X; Hu H; Wang P; Cai J Front Oncol; 2022; 12():1017737. PubMed ID: 36387113 [TBL] [Abstract][Full Text] [Related]
2. Affibody-based molecular probe Hu X; Hu H; Li D; Wang P; Cai J Open Med (Wars); 2024; 19(1):20241027. PubMed ID: 39247440 [TBL] [Abstract][Full Text] [Related]
3. A Pretargeted Imaging Strategy for Immune Checkpoint Ligand PD-L1 Expression in Tumor Based on Bioorthogonal Diels-Alder Click Chemistry. Qiu L; Tan H; Lin Q; Si Z; Mao W; Wang T; Fu Z; Cheng D; Shi H Mol Imaging Biol; 2020 Aug; 22(4):842-853. PubMed ID: 31741201 [TBL] [Abstract][Full Text] [Related]
4. Noninvasive Evaluation of Tumoral PD-L1 Using a Novel Hu B; Ma X; Shi L; Liu T; Li L; Yao M; Li C; Jia B Mol Pharm; 2024 Apr; 21(4):1977-1986. PubMed ID: 38395797 [TBL] [Abstract][Full Text] [Related]
5. In Vivo Imaging of the Programmed Death Ligand 1 by González Trotter DE; Meng X; McQuade P; Rubins D; Klimas M; Zeng Z; Connolly BM; Miller PJ; O'Malley SS; Lin SA; Getty KL; Fayadat-Dilman L; Liang L; Wahlberg E; Widmark O; Ekblad C; Frejd FY; Hostetler ED; Evelhoch JL J Nucl Med; 2017 Nov; 58(11):1852-1857. PubMed ID: 28588151 [TBL] [Abstract][Full Text] [Related]
6. Nuclear imaging-guided PD-L1 blockade therapy increases effectiveness of cancer immunotherapy. Gao H; Wu Y; Shi J; Zhang X; Liu T; Hu B; Jia B; Wan Y; Liu Z; Wang F J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33203663 [TBL] [Abstract][Full Text] [Related]
7. Noninvasive Imaging of Tumor PD-L1 Expression Using [ Zhang Y; Ding Y; Li N; Wang S; Zhou S; Li R; Yang H; Li W; Qu J Mol Pharm; 2023 Jan; 20(1):690-700. PubMed ID: 36541699 [TBL] [Abstract][Full Text] [Related]
8. Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine. Ahlgren S; Wållberg H; Tran TA; Widström C; Hjertman M; Abrahmsén L; Berndorff D; Dinkelborg LM; Cyr JE; Feldwisch J; Orlova A; Tolmachev V J Nucl Med; 2009 May; 50(5):781-9. PubMed ID: 19372467 [TBL] [Abstract][Full Text] [Related]
10. Molecular design and optimization of 99mTc-labeled recombinant affibody molecules improves their biodistribution and imaging properties. Wållberg H; Orlova A; Altai M; Hosseinimehr SJ; Widström C; Malmberg J; Ståhl S; Tolmachev V J Nucl Med; 2011 Mar; 52(3):461-9. PubMed ID: 21321280 [TBL] [Abstract][Full Text] [Related]
11. Early Phase I Study of a Xing Y; Chand G; Liu C; Cook GJR; O'Doherty J; Zhao L; Wong NCL; Meszaros LK; Ting HH; Zhao J J Nucl Med; 2019 Sep; 60(9):1213-1220. PubMed ID: 30796165 [TBL] [Abstract][Full Text] [Related]
12. In vivo imaging characterization and anticancer efficacy of a novel HER2 affibody and pemetrexed conjugate in lung cancer model. Jiao H; Zhao X; Liu J; Ma T; Zhang Z; Zhang J; Wang J Nucl Med Biol; 2019; 68-69():31-39. PubMed ID: 30578135 [TBL] [Abstract][Full Text] [Related]
13. Synthesis and preliminary biological evaluation of a novel Zhu D; Xu X; Zou P; Liu Y; Wang H; Han G; Lu C; Xie M Bioorg Med Chem Lett; 2023 Nov; 96():129496. PubMed ID: 37797805 [TBL] [Abstract][Full Text] [Related]
14. A Novel Small Cyclic Peptide-Based Liu H; Hu M; Deng J; Zhao Y; Peng D; Feng Y; Wang L; Chen Y; Qiu L Mol Pharm; 2022 Jan; 19(1):138-147. PubMed ID: 34910492 [TBL] [Abstract][Full Text] [Related]
15. Application of Fan M; Yao J; Zhao Z; Zhang X; Lu J Pharmaceuticals (Basel); 2024 Jul; 17(7):. PubMed ID: 39065756 [TBL] [Abstract][Full Text] [Related]